Tuesday, July 29th, 2025
6:15 AM – 7:45 AM Breakfast Meeting
The Westin Harbour Castle Toronto
1 Harbour Square
Toronto, ON M5J1A6
Meeting Room: Frontenac Ballroom
PROGRAM FEATURES
-
- Holographic Caregiver Avatar
- DETECT Alzheimer’s website
- Online personalized quality-improvement poster-generation portal
- DETECT Alzheimer’s Ambassador program
PRESENTING FACULTY
 |
Alireza Atri, MD, PhD Chief Medical Officer, Banner Research Banner Alzheimer’s and Research Institutes Phoenix, Sun City, and Tucson, AZ Director, Banner Sun Health Research Institute Sun City, Arizona |
 |
Scott Kaiser, MD Director of Geriatric Cognitive Health Pacific Neuroscience Institute Santa Monica, CA Adjunct Professor USC Leonard Davis School of Gerontology Los Angeles, California |
PATIENT CAREGIVER
Rev. Dr. Cynthia Huling Hummel
Owego, New York
PROGRAM OVERVIEW
Designed as an interactive case-based learning program, attendees will be guided through the latest developments in the diagnosis of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD). Expert faculty will discuss the use of validated cognitive assessments to screen for early symptomatic AD. They will also present updated diagnostic guidelines in AD, leveraging blood-based, CSF-based, and imaging biomarkers. Attendees will also learn about the importance of including the patient and their family caregiver in the assessment and diagnosis of MCI and/or Alzheimer’s disease.
TARGET AUDIENCE
This program will meet the educational needs of healthcare providers involved in the diagnosis and continued care of patients with early symptomatic AD on a global level, including specialists (ie, dementia specialists, neurologists, geriatricians, geriatric psychiatrists), nurse practitioners (NPs working in AD specialty settings), and physicians assistants (PAs working in AD specialty settings).
LEARNING OBJECTIVES
- Evaluate opportunities for the use of validated cognitive assessments to screen for early symptomatic AD within a multidisciplinary care paradigm
- Appraise updated diagnostic guidelines in AD leveraging blood-based, CSF-based, and imaging biomarkers
THE ACCREDITATION POLICY IS APPLICABLE TO EACH EVENT
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of up to 1.5 ANCC contact hours.
EACCME Credit Designation Statement
The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at [email protected]
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event Staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to the live event at [email protected]
